Yan Gao1,
Yongli Zhang2,
Yan Xi3,
Yan Chen4,
Xiling Wang5 
For correspondence:- Xiling Wang Email: xileche592189536@163.com
Accepted: 28 November 2022 Published: 29 December 2022
Citation: Gao Y, Zhang Y, Xi Y, Chen Y, Wang X. Effect of atorvastatin combined with interventional therapy for acute myocardial infarction. Trop J Pharm Res 2022; 21(12):2677-2684 doi: 10.4314/tjpr.v21i12.24
© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To evaluate the coronary thrombolytic effect of atorvastatin plus percutaneous coronary intervention (PCI) for the treatment of acute myocardial infarction.
Methods: From April 2019 to October 2020, 88 patients with acute myocardial infarction who were treated in Zhangqiu District People's Hospital were randomly assigned to receive either PCI (conventional group) or PCI plus atorvastatin (combined group). Myocardial injury index, TnI, and creatine kinase isoenzyme (CK-MB) were used to determine myocardial injury, while serum cTnI was determined using enzyme-linked immunosorbent assay (ELISA). Creatine kinase isoenzyme (CK-MB) levels were determined by immunosuppression method. Cardiac ultrasound was used to measure and compare the left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), and left ventricular end-systolic diameter (LVESD) before and after treatment in the two groups. Blood lipid levels were determined before and after drug administration, respectively, while the levels of high-density lipoprotein cholesterol (HDL-C) were determined using a colorimetric method. Total cholesterol (TC) and triacylglycerol (TG) were assessed by an enzymatic method, while low-density lipoprotein cholesterol (LDL-C) was determined using a biochemical method. Serum B-type natriuretic peptide (BNP), c-reactive-protein (CRP), and interleukin (IL)-6 levels were evaluated in an automatic biochemical analyzer. The incidence of adverse reactions during treatment, including creatinine elevation, muscle pain, and gastrointestinal reactions and their frequencies were computed.
Results: The combined group exhibited significantly lower levels of myocardial injury indices when compared with the conventional group (p < 0.05). Atorvastatin plus PCI resulted in significantly higher left ventricular ejection fraction (LVEF), and lower left ventricular end-diastolic dimension (LVEDD) as well as left ventricular end-systolic diameter (LVESD) in patients when compared with PCI alone group (p < 0.05). After treatment, the combined group showed significantly healthier levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) compared with the conventional group (p < 0.05).
Conclusion: Atorvastatin plus PCI mitigates myocardial injury and lowers cardiac function, lipid indices, serum B type natriuretic peptide (BNP), C-reactive-protein (CRP), and interleukin (IL)-6 levels. It also reduces the incidence of adverse events during treatment. Thus, this therapeutic strategy has potentials for application in the management of acute myocardial infarction.
Archives
News Updates
Fulltext in PDF